Assessing the Demand for & Strategy to Identify & Optimize Dual Payload ADC Combinations to Combat Classical Cytotoxic Resistance Mechanisms

• Contextualizing the need for novel payloads and payload combinations to circumvent resistance mechanisms to Topo1 and other classical payloads
• Breaking down a rationale-driven approach for novel payload combinations beyond dual cytotoxics
• Laying out preclinical approaches to identify and optimize dual payload combinations to set up translation for success

Speakers:

Marica Speranza

Senior Scientific Director, Innovation, Extracellular Targeted Cancer Therapeutics Research Unit

GlaxoSmithKline